Updated FDA Review Concludes That Use of Type 2 Diabetes Medicine Pioglitazone May Be Linked to an Increased Risk of Bladder Cancer

December 12, 2016. The US Food and Drug Administration (FDA) has conducted an updated review of the type 2 diabetes medication pioglitazone and confirmed that this drug may be linked to an increased risk of bladder cancer. The labels of pioglitazone-containing drugs already provide warning information regarding bladder cancer risk; this labeling will be updated with information from the current FDA review. Click here for full article